310 related articles for article (PubMed ID: 33070248)
41. A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
Park BB; Kim WS; Suh C; Hong JY; Yang DH; Lee WS; Do YR; Koh YI; Won JH; Kim MK; Jo JC; Hyun SY; Kim JA; Oh YH; Lee SS
Leuk Lymphoma; 2019 Dec; 60(13):3251-3257. PubMed ID: 31170847
[TBL] [Abstract][Full Text] [Related]
42. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
[TBL] [Abstract][Full Text] [Related]
43. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
44. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
Reboursiere E; Le Bras F; Herbaux C; Gyan E; Clavert A; Morschhauser F; Malak S; Sibon D; Broussais F; Braun T; Fornecker LM; Garidi R; Tricot S; Houot R; Joly B; Abarah W; Choufi B; Pham AD; Gac AC; Fruchart C; Marin E; Safar V; Parcelier A; Maisonneuve H; Bachy E; Cartron G; Jaccard A; Tournilhac O; Rossi C; Schirmer L; Martignoles JA; Gaulard P; Tilly H; Damaj G;
Oncotarget; 2016 Dec; 7(51):85573-85583. PubMed ID: 27458168
[TBL] [Abstract][Full Text] [Related]
45. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
46. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
[TBL] [Abstract][Full Text] [Related]
48. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
Liang X; Guo L; Hu X; Li S; Wen S
Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
[TBL] [Abstract][Full Text] [Related]
49. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis.
Xu K; Liu T; Zhang J; Zhou Y; Yang F; Ren T
Int J Clin Oncol; 2020 Sep; 25(9):1624-1634. PubMed ID: 32472208
[TBL] [Abstract][Full Text] [Related]
50. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
[TBL] [Abstract][Full Text] [Related]
51. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Wang J; Fang Y; Ma S; Su N; Zhang Y; Huang H; Li Z; Huang H; Tian X; Cai J; Xia Y; Liu P; Cai Q
Leuk Res; 2021 Dec; 111():106705. PubMed ID: 34534908
[TBL] [Abstract][Full Text] [Related]
52. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
53. Use of metronomic chemotherapy in oncology: results from a national Italian survey.
Collovà E; Sebastiani F; De Matteis E; Generali D; Aurilio G; Boccardo F; Crispino S; Cruciani G
Tumori; 2011; 97(4):454-8. PubMed ID: 21989433
[TBL] [Abstract][Full Text] [Related]
54. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.
Bennani NN; Kim HJ; Pederson LD; Atherton PJ; Micallef IN; Thanarajasingam G; Nowakowski GS; Witzig T; Feldman AL; Ansell SM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35750419
[TBL] [Abstract][Full Text] [Related]
55. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
56. Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome?
Pileri A; Pellegrini C; Agostinelli C; Grandi V; Patrizi A; Zinzani PL; Pimpinelli N
Eur J Dermatol; 2017 Feb; 27(1):49-53. PubMed ID: 27873737
[TBL] [Abstract][Full Text] [Related]
57. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification.
Kim K; Kim WS; Jung CW; Im YH; Kang WK; Lee MH; Park CH; Ko YH; Ree HJ; Park K
Eur J Cancer; 2002 Jan; 38(1):75-81. PubMed ID: 11750843
[TBL] [Abstract][Full Text] [Related]
58. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas.
Karakas T; Bergmann L; Stutte HJ; Jäger E; Knuth A; Weidmann E; Mitrou PS; Hoelzer D
Leuk Lymphoma; 1996 Dec; 24(1-2):121-9. PubMed ID: 9049968
[TBL] [Abstract][Full Text] [Related]
59. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
[TBL] [Abstract][Full Text] [Related]
60. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
